NASDAQ: ALPN - Alpine Immune Sciences, Inc.

Yield per half year: -88.05%
Sector: Healthcare

Share chart Alpine Immune Sciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.

More details
Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.0017
EBITDA -0.0415
Число акций ао 0.05 млрд
P/S 41.04
P/BV 2.42
EV/EBITDA -1.73
Цена ао 64.4
ISIN US02083G1004
Сайт https://www.alpineimmunesciences.com
Валюта usd
IPO date 2015-06-17
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: 0% (7.7)
Change price per week: 0% (7.7)
Change price per month: -88.15% (64.97)
Change price per 3 month: -1.28% (7.8)
Change price per half year: -88.05% (64.43)
Change price per year: -24.51% (10.2)
Change price per 3 year: -36.52% (12.13)
Change price per 5 year: +58.11% (4.87)
Change price per year to date: -42.84% (13.47)
All parameters

Underestimation

Title Value Grade
P/S 16.49 1
P/BV 2.96 6
P/E 0 0
EV/EBITDA -21.45 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -8.43 0
ROE, % -9.81 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.227 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % 3363.29 10
Yield Ebitda, % 5.24 1
Yield EPS, % -72.26 0
Total: 4.2
More

Institutions Volume Share, %
Decheng Capital LLC 7083288 10.81
Decheng Capital Management III (Cayman), LLC 6708288 10.23
RA Capital Management, L.P. 4909763 7.49
Lynx1 Capital Management Lp 3813926 5.82
Great Point Partners LLC 3703433 5.65
Paradigm Biocapital Advisors LP 3176743 4.85
Frazier Life Sciences Management, L.P. 3131008 4.78
Blackrock Inc. 3058498 4.67
Cormorant Asset Management, LP 2550000 3.89
Orbimed Advisors LLC. 2535245 3.87



Head Job title Payment Year of birth
Dr. Mitchell H. Gold M.D. Executive Chairman & CEO 1.02M 1968 (56 years)
Dr. Stanford Peng M.D., Ph.D. President and Head of Research & Development 940.1k 1971 (53 years)
Mr. Paul Rickey Senior VP, CFO, Treasurer & Secretary 691.1k 1979 (45 years)
Dr. Remy Durand Ph.D. Chief Business Officer N/A 1985 (39 years)
Ms. M. Christina Yi Chief Technology Officer N/A 1977 (47 years)
Temre Johnson Head of IR & Corporate Communications
Dr. Wolfgang Dummer M.D., Ph.D. Chief Medical Officer 1966 (58 years)

Address: United States, Seattle. WA, 188 East Blaine Street - open in Google maps, open in Yandex maps
Website: https://www.alpineimmunesciences.com